<DOC>
	<DOC>NCT00554450</DOC>
	<brief_summary>The purpose of the study is to assess the effect of dapagliflozin on renal glucose clearance in type 2 diabetic subjects with mild, moderate, and severe renal impairment compared to type 2 diabetic and healthy subjects with normal renal function</brief_summary>
	<brief_title>Renal Impairment in Type 2 Diabetic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Key Subjects in the following groups: Group A: Healthy Subjects with Normal Renal Function (CLcr &gt; 80 mL/min) Group B: Diabetic Subjects with Normal Renal Function (CLcr &gt; 80 mL/min) Group C: Diabetic Subjects with Mild Renal Impairment (CLcr &gt; 50 ≤80 mL/min) Group D: Diabetic Subjects with Moderate Renal Impairment (CLcr ≥ 30 ≤50 mL/min) Group E: Diabetic Subjects with Severe Renal Impairment (CLcr &lt; 30 mL/min) (and not receiving dialysis) Men and WOCBP, ages 18 to 79 years old Standard Exclusion Criteria, plus: History of diabetic ketoacidosis HbA*1c &gt; 10% Serum albumin &lt; 2.0 gm/dL Potassium &lt; 3.0 or &gt; 6.0 mEq/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>